PT  - JOURNAL ARTICLE
AU  - WARM, MATHIAS
AU  - KATES, RONALD
AU  - MALLMANN, PETER
AU  - DICK, MICHÈLLE
AU  - NAWROTH, FRANK
AU  - HARBECK, NADIA
AU  - PAEPKE, STEFAN
AU  - THOMAS, ANKE
TI  - Impact of Tumor Biological Factors on Response to Pre-operative Epirubicin and Paclitaxel Chemotherapy in Primary Breast Cancer
DP  - 2007 Mar 01
TA  - Anticancer Research
PG  - 1031--1038
VI  - 27
IP  - 2
4099  - http://ar.iiarjournals.org/content/27/2/1031.short
4100  - http://ar.iiarjournals.org/content/27/2/1031.full
SO  - Anticancer Res2007 Mar 01; 27
AB  - Background: The objective of this study was to determine the predictive impact of several established tumor biological factors (progesterone receptor, estrogene receptor, HER2/neu, and Ki-67) on response to pre-operative combination chemotherapy with epirubicin and paclitaxel in a representative group of primary breast cancer patients. Patients and Methods: Thirty-eight primary breast cancer patients (metastasis-negative) received pre-operative chemotherapy with epirubicin and paclitaxel. The response characteristics analyzed included pathological complete response and partial remission determined by 3D ultrasound, as well as down-staging and breast conserving surgery. Results: Pathologically complete response occurred in six patients. Overexpression of HER2/neu, low (negative) hormone receptors and high Ki-67 were all significant positive predictive factors for response to pre-operative chemotherapy. Conclusion: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved